PARP1 and central nervous system disorder: While several PARP inhibitors have been optimized for high CNS penetration, a critical feature for the effective treatment of brain disorders [174], most clinically approved PARP inhibitors, such as Talazoparib, Niraparib, and Rucaparib, show poor BBB penetration, limiting their use in treating CNS disorders [175].